Spero Therapeutics, Inc. (SPRO) Earnings History
Profitable11 years of earnings data (2015–2025) · Positive TTM net income
Loading earnings history...
Spero Therapeutics, Inc. (SPRO) Earnings Overview
As of June 23, 2026, Spero Therapeutics, Inc. (SPRO) reported trailing twelve-month net income of $15M, reflecting +111.8% year-over-year growth. The company earned $0.27 per diluted share over the past four quarters, with a net profit margin of 14.4%.
Looking at the long-term picture, SPRO's historical earnings data spans multiple years. The company achieved its highest annual net income of $23M in fiscal 2023.
Spero Therapeutics, Inc. maintains positive profitability with a gross margin of 100.0%, operating margin of -0.0%, and net margin of 14.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including VNDA (-$240M net income, -102.0% margin), PRAX (-$327M net income), NAOV (-$20M net income, -712.3% margin), SPRO has outperformed on profitability metrics. Compare SPRO vs VNDA →
SPRO Earnings vs Peers
Earnings metrics vs comparable public companies
SPRO Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9M | +112.5% | $-24,000 | $0.15 | 14.4% | -0.0% |
| 2024 | -$69M | -400.6% | -$73M | $-1.27 | -142.9% | -152.9% |
| 2023 | $23M | +149.1% | $21M | $0.43 | 22.0% | 20.7% |
| 2022 | -$46M | +48.3% | -$42M | $-1.23 | -95.5% | -86.9% |
| 2021 | -$90M | -14.7% | -$88M | $-2.91 | -2923.6% | -2865.5% |
| 2020 | -$78M | -28.5% | -$79M | $-3.52 | -839.0% | -847.9% |
| 2019 | -$61M | -46.2% | -$63M | $-3.31 | -335.7% | -348.4% |
| 2018 | -$42M | +9.6% | -$43M | $-2.60 | -1050.5% | -1079.3% |
| 2017 | -$46M | -80.8% | -$42M | $-17.82 | -2329.3% | -2108.6% |
| 2016 | -$25M | -151.0% | -$33M | $-3.86 | -7609.3% | -9916.7% |
| 2015 | -$10M | - | -$13M | $-1.54 | - | - |
Download Data
Export SPRO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SPRO — Frequently Asked Questions
Quick answers to the most common questions about buying SPRO stock.
What is SPRO earnings per share (EPS)?
SPRO trailing twelve-month (TTM) diluted EPS is $0.27, reflecting +111.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Spero Therapeutics, Inc.'s net income?
Spero Therapeutics, Inc. (SPRO) trailing twelve-month net income is $15M as of 2025. Earnings grew +111.8% year-over-year.
Is SPRO profitable?
Yes, SPRO is profitable with a TTM net income of $15M and a net profit margin of +14.4%.
What is SPRO's earnings growth rate?
SPRO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are SPRO's profit margins?
Spero Therapeutics, Inc. net profit margin is +14.4%, operating margin is -0.0%, and gross margin is +100.0%. Margins are within a typical range for the sector. Return on Equity is +16.3%.
Is SPRO growing earnings?
Yes, SPRO earnings are accelerating — EPS growth of +111.8% exceeds the 5-year CAGR of N/A. TTM net income reached $15M. Earnings momentum is strengthening.
What was SPRO's best earnings year?
Spero Therapeutics, Inc.'s highest annual net income on record is $23M, achieved in fiscal year 2023. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were SPRO's earnings last quarter?
SPRO's most recent reported quarter was Q1 2026. Net income was $-7M with diluted EPS of $-0.13. For a full breakdown of all quarters, see the quarterly earnings table on this page.